Difference between revisions of "Tivozanib (Fotivda)"
Jump to navigation
Jump to search
m |
m (Jwarner moved page Tivozanib (AV-951) to Tivozanib (Fotivda): EMA approval with brand name) |
(No difference)
| |
Revision as of 00:47, 17 February 2021
Mechanism of action
From the NCI Drug Dictionary: An orally bioavailable inhibitor of vascular endothelial growth factor receptors (VEGFRs) 1, 2 and 3 with potential antiangiogenic and antineoplastic activities. Tivozanib binds to and inhibits VEGFRs 1, 2 and 3, which may result in the inhibition of endothelial cell migration and proliferation, inhibition of tumor angiogenesis and tumor cell death.
Diseases for which it is used
History of changes in FDA approval
Not currently FDA approved for any indication.
Also known as
- Code name: AV-951
- Brand name: Fotivda